Radiopharmaceuticals for bone malignancy therapy.
This continuing education article reviews radionuclide bone therapy agents that are available commercially and introduces agents that are being evaluated for future use. Currently these agents are used to provide pain palliation from metastases to bone. Future applications may include adjuvant therapy to surgery or external beam treatment. After reading this paper, the reader should be able to: (a) describe the desirable characteristics of radionuclide bone therapy agents; (b) compare and contrast radiopharmaceuticals available for bone therapy; and (c) state the clinical applications of radionuclide bone therapy agents.
Atkins
H L
HL
Medical Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA.
Srivastava
S C
SC
D001853:Bone Marrow / Q000528:radiation effects; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery; D001842:Bone and Bones / Q000528:radiation effects; D006801:Humans; D010146:Pain / Q000532:radiotherapy; D010166:Palliative Care; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant
D019275:Radiopharmaceuticals